Ep 132 - Aceclidine's Role As A Presbyopia Treatment - Dr. Marc Odrich

Dr. Marc Odrich is Chief Medical Officer at LENZ therapeutics and has decades of experience in private practice, teaching, and medical research that contributes to LENZ Therapeutics success by driving the clinical trial and approval of our novel products. His expertise in authoring and directing over 25 clinical trials throughout his career makes him uniquely qualified to execute the approval process. In addition to his duties as Chief Medical Officer, Dr. Odrich is an Associate Professor of Ophthalmology at the University of Virginia, where he practices and teaches Clinical Ophthalmology specializing in Refractive Surgery and Ocular Surface Disease. He is also the Chief Medical Officer for TearSolutions, Inc., a startup in clinical trials for a new drug developed for dry eye disease. In addition, he is a consultant and member of the Board of Directors for CXLO, Inc., a developer of an innovative treatment for keratoconus and other corneal ectasias, as well as a consultant and medical monitor for Johnson & Johnson’s refractive products. Previously, he played pivotal roles in the development and commercialization of the Excimer and Femto lasers as Medical Director at Visx. Dr. Odrich is a graduate of Columbia College and received his medical degree from Columbia University College of Physicians and Surgeons. He completed an internship in internal medicine at Yale’s Danbury Hospital before moving to pursue his residency at Columbia’s Harkness Eye Institute. Odrich then completed a two-year fellowship focused on cornea and external disease at Harvard’s Massachusetts Eye and Ear Infirmary.